GREEN CROSS

Search
Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
close
Total Menu KOR
close

About usResponsibility

Aspiring to become a leader of the global health industry, Green Cross is working to make the world safer and healthier.

kids

Having achieved its first major success in the early 1980s with the development of Hepavax, a hepatitis-B vaccine, Green Cross established the Mogam Institute for Biomedical Research (now the Mogam Biotechnology Institute) in 1984, the first nonprofit research foundation to be established by the private sector in Korea. The Mogam Institute researches and develops a wide range of pharmaceuticals for prevention, diagnosis, and treatment of disease, with an unwavering commitment over three decades to exploring the scientific causes and mechanisms of various life phenomena and contributing to the health of the nation and the world. The Institute has successfully developed and commercialized a number of key medicines, including vaccines (such as Suduvax, the varicella vaccine), a recombinant interferon, a G-CSF and other protein-based treatments, and HIV and HCV diagnostic products. Through its extensive knowledge and experience, the Institute continues to invest in the acquisition of additional personnel and technology, with a focus on vaccines, cancer, infectious diseases, and rare and neglected diseases.

Since introducing an antihemophilic factor (AHF) treatment for hemophilia patients in 1974, Green Cross has supported the creation and expansion of a more systematic and effective treatment environment for patients with hemophilia, which is a congenital and hereditary disease. An example of this effort is the Korea Hemophilia Foundation (KHF), which the company established in 1990 with the help of the Hemophilic Rehabilitation Society. The KHF today includes a specialized clinical center for hemophilic patients, through which it provides free tests and financial aid for medical care. Green Cross also began in 2016 to provide GreenGene F 600 IU free of charge to developing countries under a three-year partnership agreement with the World Federation of Hemophilia.

voluntary service
examination

Green Cross employees and executives, as members of the company’s Social Volunteer Corps, regularly participate in a variety of social campaigns and causes, including blood donation drives at all Green Cross business locations. Green Cross also sponsors the Matching Grant Program, in which the company matches donations made by employees and executives to provide financial support to those in need.